-+ 0.00%
-+ 0.00%
-+ 0.00%
ACRIVON ANNOUNCES LATE-BREAKING ORAL PLENARY PRESENTATION OF EARLY PHASE 1/2 CLINICAL RESULTS IN AP3-PREDICTED TUMORS FOR ITS FIRST-IN-CLASS WEE1/PKMYT1 INHIBITOR ACR-2316 AT THE 38TH EORTC-NCI-AACR SYMPOSIUM
Share

Please log in to view news

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending